Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Stage IV
Interventions: DRUG: Tucatinib
Sponsor: Providence Health & Services
Collaborators: Seagen Inc.